55 results about "Lipogenesis" patented technology

The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening / diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues.

The present invention provides a novel method for inhibiting sugar-induced weight gain resulting from fructose and glucose driven lipogenesis. The method for inhibiting sugar-induced weight gain is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants to a host in need thereof. The present also includes novel methods for the prevention and treatment of diseases and conditions resulting from high carbohydrate ingestion. The method for preventing and treating these sugar-induced diseases and conditions is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and / or isolated from a single plant or multiple plants, preferably in the Scutellaria and Acacia genus of plants and a pharmaceutically acceptable carrier.

The present invention relates to a nutritional product, dietary supplement or pharmaceutical composition for the treatment of acne and related skin disorders. The invention also relates to a composition having a combination of ingredients such that it reduces symptoms associated with acne and related skin disorders. The invention relates to such a composition containing a variety of vitamins, minerals and one or more herbal medicine sources. In one preferred embodiment, the vitamins, minerals and one or more herbal medicine sources are present in an amount such that its mechanism of action is through inhibition of the growth of Propionobacterium acnes (P. acnes) and the inhibition of lipogenesis of sebum production. In another preferred embodiment, the invention contains a Vitamin A source to normalize keratinoid maturation, proliferation and turnover of skin cells. In another preferred embodiment, the invention further contains at least one of a Vitamin E source or Selenium. In another preferred embodiment, the invention further contains at least one of a Vitamin B6 source, a Pantothenic Acid source, Zinc or any active salt, and Chromium or any active salt. In another preferred embodiment, the invention further contains any one or more of an herbal source of Berberis aquifolium (Oregon grape root), Barberis vulgaris (barberry), Hydrastis Canadensis (goldenseal), or other herbal source of the compound berberine. The present invention also relates to a method of administering a therapeutically effective amount of the combination of ingredients for the treatment of acne and related skin disorders.

The invention discloses a high-fiber sugarless bean dreg biscuit and a processing method thereof. The invention is characterized in that the bean dreg biscuit is prepared from the following raw materials in portions by weight: 100 portions of flour, 40-60 portions of dry bean dreg powder, 40 portions of corn starch, 25 portions of water, 16 portions of edible vegetable oil, 10 portions of egg, proper amount of swelling agent, proper amount of edible salt and proper amount of flavor. By fully utilizing the abundant proteins and celluloses and low fat content of the bean dregs, the invention can decelerate the absorption of the excess sugar by human bodies, eliminate the hunger sensation and inhibit the lipogenesis, thereby achieving the effect of losing weight.

A full-value feed for Estuarine puffer contains fish meal, starch, skin milk powder, spirulina, L-methionine, active glutelin, choline chloride, beer yeast and puffed soybean. It features rich nutrients.

The present invention relates to methods and compositions for modulating lipogenesis, lipid accumulation and lipid metabolism in a cell. These methods and compositions modulate genes which are controlled by LXRα, including the lipogenic transcription factor SREBP-1c.

The invention discloses herbal tea containing L-arabinose. The herbal tea comprises the following ingredients according to weight percent: 0.002%-10% of L-arabinose, 0.02%-3% of D-xylose, 0.2%-8% of stachyose, 0-15% of cane sugar and 64%-99.773% of pure water, and a proper quantity of food additives can be further added into the herbal tea. The herbal tea can regulate blood sugar level, reduce blood fat and relieve lipogenesis, solves the problem that the conventional herbal tea with high sugar and heat and low nutrition is not suitable for people wth diabetes, adiposis and the like, has a function of gut purging to solve the problems of constipation and toxin accumulation of people, can further dispel the effects of alcohol to protect the liver so as to solve the problem that the liver is damaged as people drink too much alcohol, and therefore, the herbal tea is healthy food for preventing diabetes, loosing weight, relaxing the bowels and protecting liver.

Biomarkers relating to de novo lipogenesis are provided, as well as methods for using such biomarkers in an Index to assess DNL. In addition, methods for diagnosing, determining predisposition to, and monitoring progression / regression of diseases related to DNL are provided. Also provided are methods of monitoring the efficacy of treatments for diseases related to DNL as well as other methods based on biomarkers of DNL.

Methods of culturing sebocyte cells, isolated populations of sebocytes, and methods of using the cultured sebocyte cells for screening compounds that inhibit or activate lipogenesis are provided.

Optical methods and devices are provided for the reduction of the lipid content of adipocytes without significant heat or intolerable adverse effect on the cells and their surrounding tissues. The optical method and device can be used to irradiate adipose tissue through the skin with non-thermal and non-destructive effects by application of near infrared (NIR) irradiation at selected wave bands in selected ranges to affect modulation of innate enzymatic processes involved in lipolysis, lipogenesis, leptin secretion, adiponectin secretion, and / or glucose absorption.

The invention discloses a low fat chicken raising method, which comprises controlling growth velocity, and controlling lipogenesis through shortening feed time, wherein only plant fodder formulation is employed, and animal fat and feed stuff are strictly prohibited. By adopting different fodder formulation based on the physiological requirements of various growth phases of the chickens, the lipogenesis can be regulated and controlled.

A peptide and a peptide complex of the present invention exhibit an anti-obesity effect by inhibiting fat accumulation and decomposing already accumulated fat, and exhibit an excellent effect with respect to diabetes by effectively reducing blood sugar. The peptide and the peptide complex of the present invention decrease the expression of PPARγ, ACC, and aP2, which are adipogenic markers, increase the expression of pHSL, AMPK-α1, CGI-58, and ATGL, which are lipolytic factors, and reduce the size of fat cells and blood cholesterol values. The peptide and the peptide complex of the present invention, which have excellent activity and safety, can be advantageously applied to drugs and quasi-drugs.

The invention discloses a method for quickly detecting RFLP (restriction fragment length polymorphism) of SNP (single nucleotide polymorphism) of a common ox SIRT1 (silent information regulator 1) gene promotor region. The method comprises the following steps of: taking whole genome DNA (deoxyribonucleic acid) of common ox blood as a template and a primer pair P (F and R) as a primer; performing PCR (polymerase chain reaction) amplification on the common ox SIRT1 gene promotor region; digesting a PCR amplification product by using restriction endonuclease SmaI; performing agarose gel electrophoresis on segments after enzyme digestion; and identifying the SNP of the common ox SIRT1 promotor region according to a result of the agarose gel electrophoresis. Because important functions including muscle differentiation, lipogenesis and the like related to the SIRT1 are closely related to common ox meat quality characteristics, and the SNP can significantly affect the promotor activity of the SIRT1 gene and is related to various important economic characteristics of the common ox, the detection method provided by the invention lays a foundation for the establishment of the relationship between the SNP and growth characteristics of the SIRT1 gene, and can be used for marker assisted selection of the growth characteristics of the Chinese common ox so as to facilitate rapid establishment of common ox populations with excellent genetic resources.

The invention discloses novel stilbene compound oligomers in sword iris (Iris lacteal Pall .var .chinensis(Fisch .)Koidz .) seed kernels as well as an extraction method and usage thereof. The extraction method of the novel stilbene compound oligomers in the sword iris seed kernels comprises the following steps: performing amplified preparation on an alkali extracted and acid precipitated product of sword iris seed kernels; and then, carrying out two times of preparation by adopting an aqueous cetonitrile solution as mobile phase so as to obtain the novel stilbene compound oligomers S11 in thesword iris seed kernels, namely VitisinA-13b-o-glucoside. The invention further provides application of the new compound S11 in preparation of medicines used for preventing and / or treating lipid metabolism disorder. And moreover, inhibition of cell lipogenic differentiation and lipogenesis by the novel stilbene compound oligomers S11 is verified by studying activity of the novel stilbene compoundoligomers S11; so that, the novel stilbene compound oligomers S11 can be used for preparing medicines which are capable of preventing or treating metabolic disorders, such as obesity, hyperlipidemia and the like.

The present invention provides a compound comprising a helminth-derived glycan and / or glycoconjugate thereof (e.g., a compound comprising a Lewisx antigen (e.g., LNFPIII), a non-Lewisx antigen (e.g., LNnT, LDN, and LDN derivatives), or a mixture of Lewisx and non-Lewisx antigens (e.g., SEA)), useful as a therapeutic compound for treating or preventing diseases associated with fat accumulation in the liver. The compounds of the invention are useful for treating or preventing the development of a fatty liver disease in a subject that has the disease or is at risk of developing the disease, and inhibiting lipogenesis in hepatocytes. The invention also provides methods of regulating the Erk-c-fos / AP-1-FXRα signalling pathway by administering a compound comprising a helminth-derived glycan and / or glycoconjugate thereof to a subject with a fatty liver disease, or contacting a hepatocyte with a compound comprising a helminth-derived glycan and / or glycoconjugate thereof.

The invention belongs to the technical field of metal-organic frameworks, and discloses a ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold, a preparation method and application, and the preparation method of the ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold comprises the steps of construction of an SIM-ZIF-8 drug-loaded system and construction of the SIM-ZIF-8 / PEGDA / SA hydrogel. The novel ZIF-8 drug-loaded hydrogel osteogenesis-promoting scaffold is SIM-ZIF-8 / PEGDA / SA. According to the invention, an in-situ synthesis method is adopted to load SIM in a ZIF-8 pore structure (SIM-ZIF-8), and the biochemical microenvironment of bone tissues is improved, so that the dual effects of lowering lipid and forming bones are achieved. According to the invention, the ZIF-8 is loaded with an SIM small molecule drug for the first time, and the finally formed SIM-ZIF-8 system can reduce fat formation and promote osteogenesis under a high fat condition, and has a good application prospect in treatment of bone metabolic diseases caused by hyperlipidemia.

The invention discloses a fat management composition, a preparation method and an application. The fat management composition consists of the following components in parts by weight: 12-20 parts of L-carnitine, 11-20 parts of tea saponin, 5-11 parts of chitosan, 3-8 parts of anthocyanin, 1-3 parts of a bamboo leaf extract and 1-6 parts of limonin. The product (the fat management composition) provided by the invention, which is prepared from the L-carnitine, the tea saponin, the chitosan, the anthocyanin, the bamboo leaf extract and the limonin, has functions of promoting fat metabolism, improving a cell energy metabolic rate and inhibiting fat formation, and in addition, an effect of reducing weight can be also achieved; and the preparation method is simple and is beneficial for achievingindustrial production.

AM580 and structurally related compounds have been found to be useful in treating infection by a wide range of RNA and DNA viruses, and also in reducing associated inflammation. This activity is independent of RAR-alpha signaling, and is not a result of activation of the hosts innate immune response. Broad antiviral activity of AM580 and structurally related compounds is a due to modulation of lipogenesis so as to correct disregulation of this pathway in virus-infected cells, via inhibition of nSREPBP.

The present invention relates to a pharmaceutical or food composition containing licochalcone A as an active ingredient for preventing, improving, or treating AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia). The pharmaceutical or food composition according to the present invention may significantly reduce adipocyte differentiation, adipocyte fat accumulation, and lipogenesis in hepatocytes, and may exhibit the effects of activating AMPK in hepatocytes. Accordingly, the pharmaceutical or food composition of the present invention can be effectively used for AMPK-related diseases, specifically, disorders involving lipid metabolism, hyperlipidemia, metabolic syndrome, obesity, fatty liver, or degenerative diseases (in particular, dementia).

In a composition and a microneedle for a localized obesity treatment containing the same in accordance with the present disclosure, the composition in accordance with the present disclosure contains a gelatin, decomposes a fat in a body, and inhibits lipogenesis and fat deposition in the body.

The invention relates to a compound serving as PPAR gamma ligand and the application thereof, and discovers that antibiotic ionomycin relates to novel ligand which can be bound with PPAR gamma with high affinity binding and specificity. The ligand has similar capability to traditional PPAR gamma activating agent, such as rogridone, on terms of restraining CDK5 to perform phosphorylation to PPAR gamma, has the property of adjusting blood sugar metabolic balance through PPAR gamma and further improving the low sensibility of II type diabetes insulin, and can better improve a series of iconic indexes of diabetes. In addition, ionomycin has low transcriptional activation capability and obviously lower side effects, such as lipogenesis and weight gain inducing, than that of rogridone-the ligand of PPAR gamma. The compound provides a three dimensional crystal structure of ionomycin and PPAR gamma which are mutually bound through X-ray crystal diffraction and reveals a special binding model of ionomycin in a PPAR gamma ligand binding domain at the atomic level, and the structure is obviously different from rogridone / PPAR gamma protein complex belonging to thiazolidinedione.

The present document describes apple peel polyphenolic extract comprising a proanthocyanidin content of at least 15000 μg / g of dry weight, comprising about 30% to about 35% epicatechin content, and pharmaceutical composition comprising the apple peel polyphenolic extract. The present document also describes methods and use of the apple peel polyphenolic extract for preventing or treating conditions such as oxidative stress, inflammation and mitochondrial dysfunction of the liver, insulin resistance, intestinal endothelial tissue injury, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis (NASH), liver fibrosis, liver cirrhosis, and / or inhibition of de novo lipogenesis and β-oxidation of free fatty acids for preventing accumulation thereof in the liver. The present document also describes a process for extraction of at least a polyphenol content from dry apple peel powder.

Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets. Accordingly, the present invention relates to methods and pharmaceutical compositions for modulating autophagy based on the modulation of the activity or expression of DBI.

The present invention discloses a fat eliminating and health preserving sweet orange drink which is prepared from the following raw materials by weight: 600-650 parts of sweet orange, 50-60 parts of strawberry, 20-25 parts of oats, 8-10 parts of apple enzyme powder, 15-20 parts of wine lees, 3-5 parts of winter collybia stipe dietary fibers and the like. The winter collybia stipe dietary fibers and psyllium shell powder contain soluble dietary fibers which can help human body to expel residues, and linden, chrysanthemum, garcinia pedunculata and the like are matched to achieve effects of slimming and swelling subsiding, and can inhibit lipogenesis to achieve the purpose of fat eliminating.

The present invention provides a method for reducing the expressions of the sterol regulatory element-binding protein 1C (SREBP-1C), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase 1 (SCD-1), comprising administering to a subject a composition comprising an effective amount of a longan pericarp extract. The longan pericarp extract significantly inhibits lipogenesis, reduces the glutamic-pyruvic transaminase (GPT) index, and protects the liver.

Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later.

The invention discloses a multi-drug combined rehabilitation granule for type 2 diabetes and application thereof. The multi-drug combined rehabilitation granule is formed by compounding of the following components by weight percentage: 45-90% of sorbitol, 5-50% of betaine or betaine hydrochloride, and 0.01-10% of Span-60. The sorbitol involved in the invention enables dissolved fat to form a stable emulsion or ultra microemulsion, with a molecular structure similar to that of glucose molecules, sorbitol can simulate glucose molecules to play a targeted positioning role, also has certain sweetness and can improve the taste of the granule; betaine / betaine hydrochloride is a biosurfactant, can assist dissolution of fat, also has liver protection function, and can improve the insulin utilization efficiency; and Span-60 can gradually dissolve fat deposited on a channel surface. The granule provided by the invention can make fat deposited on the surfaces of channels and semipermeable membranes form a stable "oil-in-water" emulsion or ultra microemulsion, deposited fat can be dissolved and then discharged out of the body through an excretory system, and the utilization efficiency of insulin can be improved.